louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04363970: Early Removal of the Urethral Catheter Following Trans-urethral Resection of Prostate
Official title: Early Versus Delayed Removal of the Urethral Catheter After Trans Urethral, Randomized Clinical Trial.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Urinary Retention
Keywords: Benign Prostate Hyperplasia
Urinary retention
Re-catheterization
Lead sponsor: University of Jordan
Sponsor class: OTHER
First posted: 2020-04-27
Enrollment: 200
Sex: MALE
Minimum age (years): 45
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 200 adult males from urology clinic atJordan university hospital, with benign prostate hyperplasia who undergo trans-urethral resection of the prostae will be included in this study,

Brief summary: Transurethral resection of prostate is the gold standard operation for bladder outflow obstruction due to benign prostatic enlargement. However, catheter removal day is variable. The objective of this study is to compare early and delayed catheter removal groups in terms of, urinary retention after catheter removal, length of hospital stay, weight of resected prostate, duration of resection, peri-operative blood transfusion, and postoperative complications.

Detailed description: This randomized controlled trial will carried out in Urology clinic at Jordan university hospital. Patients with benign prostate hyperplasia will be selected by simple random sampling technique after taking informed consent and will divided into two groups: Group A- early catheter removal group( catheter removed after 24 hours) and Group B-delayed catheter removal group ( catheter removed after 48 hours). in this study we will exclude patients with large post-void urine volume, simultaneous internal urethrotomy and transurethral resection of prostate, co-morbidity( diabetes mellitus, CVA) spinal cord injury, urethral stricture, prostate cancer proved by biopsy and intra-operative complications. Patients will discharged after removal of catheter if they voided successfully.

Eligibility criteria: Inclusion Criteria:

- All men with benign prostate hyperplasia who planned to undergo TURP will be included in this study.

Exclusion Criteria:

* Large post void residual urine.
* Simultaneous internal urethrotomy and TURP.
* Uncontrolled Diabetes Mellitus (DM).
* Cerebrovascular accident accident (CVA).
* Spinal cord injury.

Primary outcomes:
measure: urinary retention
timeFrame: after 3 months.
Secondary outcomes:
measure: Lower urinary tract symptoms
timeFrame: after 3 months.
Other outcomes:
Locations:
city: Amman
country: Jordan
facility: Saddam Al Demour
Study officials:
affiliation: Jordan University Hospital
name: Saddam Al Demour, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00402870: Postoperative Analgesic Requirements for the ProSeal Laryngeal Mask Airway Versus the Tracheal Tube in Females Undergoing Gynecological Laparoscopic Surgery
Official title: Postoperative Analgesic Requirements for the ProSeal Laryngeal Mask Airway Versus the Tracheal Tube in Females Undergoing Gynecological Laparoscopic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intubation
Lead sponsor: Medical University Innsbruck
Sponsor class: OTHER
First posted: 2006-11-22
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The ProSeal laryngeal mask airway is a relatively new airway device with a modified cuff to increase the seal and a drain tube to provide a channel for regurgitated fluid, prevention of gastric insufflation and insertion of a gastric tube. In the following randomized prospective double-blind trial, we test the hypothesis that the postoperative analgesic requirements is higher for the ProSeal laryngeal mask airway than the tracheal tube.


Eligibility criteria: Inclusion Criteria:

* Female
* ASA I-II
* Age 18-75
* Elective laparoscopic surgery

Exclusion Criteria:

* Known or predicted difficult airway
* Oropharyngeal pathology
* Mouth opening \< 3.0 cm
* A body mass index \> 35 kg m-2
* Increased risk of aspiration
* Inability to communicate or understand the visual analogue scale
* Analgesics within 24 hours of surgery

Primary outcomes:
measure: Postoperative analgesia
timeFrame: 24 hrs
Secondary outcomes:
Other outcomes:
Locations:
city: Innsbruck
country: Austria
facility: Dept of Anesthesia
Study officials:
affiliation: Dept of Anesthesia, Medical University Innsbruck
name: Christian Keller, MD, M.Sc.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04022070: The Effect of Dynamic Tape ® on Plantar Fascitis
Official title: Short-term Effect of Dynamic Tape ® on Plantar Fascitis; a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fasciitis, Plantar
Foot Tapping
Keywords: foot
fasciitis
tapping
Lead sponsor: University of Seville
Sponsor class: OTHER
First posted: 2019-07-16
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Patients with fasciitis plantar pain
Primary purpose: TREATMENT

Brief summary: The Dynamic Tape ® (DT) is a new Tape (2009). Dynamic tape ® is a visco-elastic nylon tape material , greater than 200% elastic has manufactured in Asia. The material and adhesive arefast drying and breathable meaning that the tape, if it is correctly applied may stay on for up to 5 days, bearingin mind that if any discomfort, itching, burning, stinging orirritation is felt immediate removal is strongly advised.

Usually tapes are applied in plantar fasciitis to improve the symptoms. The fasciitis plantar is an pain that sometimes incapacitates the physical activity of the patients.

Detailed description: Objective: To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage in a sample of 15 amateur athletes affected by plantar fasciitis. The assessment will be performed using an analogue visual scale (EVA). Material and methods: the aim of the study is to evaluate a group of 15 amateur athletic subjects , all individuals suffering plantar fasciitis without any previous or current treatment. The age, from 18 to 65 years old. Samplings will be performed intentionally without a control group.

The control group will use a Low-dye tape and will be evaluated before and after a week

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of fasciitis
* Plantar fasciitis pain

Exclusion Criteria:

Current treatment of fasciitis pain

Primary outcomes:
measure: Plantar fasciitis pain
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Sevilla
country: Spain
facility: Aurora Castro Mendez
Study officials:
References:
Clinical trial NCT00964470: Multi-Center, Prospective, Randomized, Comparison of AWBAT™-D vs. Xeroform™ or Glucan II™ for Treatment of Donor Sites in Burn Surgery
Official title: Multi-Center, Prospective, Randomized, Comparison of AWBAT™-D vs. Xeroform™ or Glucan II™ for Treatment of Donor Sites in Burn Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Treatment of Donor Site Burns
Keywords: Burn, donor site, skin graft, dressing, AWBAT™-D, XEROFORM™, GLUCAN II™
Lead sponsor: Aubrey Inc.
Sponsor class: INDUSTRY
First posted: 2009-08-25
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the rate of healing and the non-adherence of three types of dressings. The study will also compare rate of infection, scarring and perception of pain associated with treatment.

Detailed description: The purpose of this study is to evaluate AWBAT™-D compared to Xeroform™ or Glucan II™ for the treatment of donor sites in burn surgery.

Primary Study Goals:

* To compare the rate of healing of donor sites.
* To compare patient reported perception of pain
* To compare the potential clinical complication rates of:

  * non-adherence,
  * seroma
  * hematoma
  * infection

Secondary Study Goal:

• To compare clinical outcome of donor sites: scarring based on the Vancouver Scar Scale.

Eligibility criteria: Inclusion Criteria:

* Burn wounds measuring 1% - 30% TBSA requiring skin grafting
* Anterior bilateral donor sites of approximately the same size taken from the thighs or abdomen

Exclusion Criteria:

* Ventilator dependence
* Pregnancy /Lactation
* Mechanism of injury was electrical, chemical or frostbite
* Co-morbidity which may compromise healing
* Known allergy to porcine or porcine products

Primary outcomes:
measure: • To compare the rate of healing of donor sites. • To compare patient reported perception of pain • To compare the potential clinical complication rates of: o non-adherence, o seroma o hematoma o infection
timeFrame: 2 year follow-up
Secondary outcomes:
measure: • To compare clinical outcome of donor sites: scarring based on the Vancouver Scar Scale.
timeFrame: 2 year follow-up
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Wishard Health Services Burn Center
state: Indiana
city: Cincinnati
country: United States
facility: The University Hospital Burn Center Cincinnati
state: Ohio
city: Memphis
country: United States
facility: Firefighter's Regional Burn Center
state: Tennessee
Study officials:
References:
Clinical trial NCT00294970: Cognitive Characteristics of PTSD Patients With OCD
Official title: Cognitive Characteristics of PTSD Patients With OCD
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Post-Traumatic Stress Disorders
Obsessive-Compulsive Disorder
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2006-02-22
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Eligible patients from each group were invited to participate in the study from the inpatient, outpatient and public clinic populations of the Chaim Sheba Medical Center Psychiatric Division

Brief summary: Cognitive profile of patients who suffer both from PTSD and OCD, as compared to those who suffer from PTSD or OCD without other comorbidity.

Detailed description: Demographic data and cognitive data will be compared on PTSD, PTSD-OCD and OCD patients using a battery of computerized cognitive tests

Eligibility criteria: Inclusion Criteria:

* Patients suffer from current PTSD with no other co-morbidity
* Patients suffer from current OCD with no other co-morbidity
* Patients suffer from current PTSD and OCD

Exclusion Criteria:

* Patients suffer from PTSD and OC symptoms

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ramat-Gan
country: Israel
facility: Chaim Sheba Medical Center
Study officials:
affiliation: Sheba Medical Center
name: Joseph Zohar, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01037270: Evaluation of the Accuracy and Precision of the INRatio® Prothrombin Time (PT) Monitoring System With New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Embolism
Atrial Fibrillation
Deep Vein Thrombosis
Keywords: Patients with conditions (PE, Afib, DVT) requiring ongoing INR measurements.
Lead sponsor: Abbott RDx Cardiometabolic
Sponsor class: OTHER
First posted: 2009-12-22
Enrollment: 271
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Approximately 210 subjects on OAT and 20 normal healthy subjects not on anticoagulation therapy will be enrolled.

Brief summary: This is a multi-center study designed to evaluate the accuracy and precision of the INRatio® Prothrombin Time (PT) Monitoring System, utilizing the INRatio test strip newly designed for low sample volume and heparin insensitivity, when used by trained medical professionals for the quantitative determination of PT and International Normalized Ratio (INR) in fingerstick and venous whole blood from subjects on oral anticoagulation therapy (OAT). These results will be compared to those PT/INR results obtained on plasma from the same subjects as analyzed at a central laboratory with the Sysmex CA-560 System.


Eligibility criteria: Inclusion Criteria:

* Adults (18 years of age or older);
* Willing and able to provide written informed consent and comply with study procedures;
* Subjects on oral anticoagulation therapy. This inclusion criterion is waived for the 20 normal healthy volunteers who must NOT be on warfarin or any other anticoagulant drug.

Exclusion Criteria:

* Hematocrit less than 25 or greater than 55%;
* Lupus or antiphospholipid syndrome (APS)
* Vulnerable populations deemed inappropriate for study by the site's principal investigator.
* Already participated in this study.

Primary outcomes:
measure: Analytical accuracy and precision of the INRatio Prothrombin Time (PT) Monitoring System.
timeFrame: 3-6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Loma Linda
country: United States
facility: Loma Linda VA Hospital
state: California
city: Sacramento
country: United States
facility: UC Davis Healthcare System
state: California
city: San Diego
country: United States
facility: San Diego Cardiac Center
state: California
city: Aurora
country: United States
facility: Fox Valley Cardiology
state: Illinois
Study officials:
References:
Clinical trial NCT00972270: Trial Using Impella LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability
Official title: RECOVER II Trial: A Prospective Randomized Trial Investigating the Use of the IMPELLA RECOVER LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Acute Myocardial Infarction
Keywords: Arterial Occlusive Disease
Heart Diseases
Myocardial Ischemia
Vascular Disease
Arteriosclerosis
Ischemia
Lead sponsor: Abiomed Inc.
Sponsor class: INDUSTRY
First posted: 2009-09-04
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized trial investigating the use of the IMPELLA RECOVER LP 2.5 compared to Intra-aortic balloon pump (IABP) in patients with Acute Myocardial Infarction.


Eligibility criteria: Inclusion Criteria:

* Informed Consent
* Subject presenting with STEMI undergoing primary PCI
* Patient presents with at least 1 of the following:
* Unstable blood pressure
* Tachycardia and tissue hypoperfusion
* The need for intravenous pressor or inotropic support
* Patient presents with STEMI:
* CK-MB\>2x normal

Exclusion Criteria:

* Unwitnessed cardiac arrest
* Abnormalities of the aorta
* Recent stroke or TIA
* Mural thrombus in the left ventricle

Primary outcomes:
measure: Composite rate of major adverse events within 30 days or hospital discharge.
timeFrame: 30 days or discharge
Secondary outcomes:
measure: Maximum CPO increase from baseline.
timeFrame: Treatment
Other outcomes:
Locations:
city: Hartford
country: United States
facility: Hartford Hospital
state: Connecticut
city: Chicago
country: United States
facility: University of Chicago Medical Center
state: Illinois
city: Shawnee Mission
country: United States
facility: Shawnee Mission
state: Kansas
city: Hawthorne
country: United States
facility: Valley Hospital
state: New Jersey
city: Columbus
country: United States
facility: Ohio State University
state: Ohio
city: Columbus
country: United States
facility: Riverside Methodist
state: Ohio
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
city: Wormleysburg
country: United States
facility: Pinnacle Health
state: Pennsylvania
city: York
country: United States
facility: York Hospital
state: Pennsylvania
city: Houston
country: United States
facility: Methodist Hospital
state: Texas
city: Murray
country: United States
facility: Intermountain Medical Center
state: Utah
Study officials:
affiliation: Not affiliated with Abiomed
name: William O'Neill, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02737670: Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus
Official title: Randomized Double Blind Controlled Trial on Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Tinnitus, Subjective
Lead sponsor: St Joseph University, Beirut, Lebanon
Sponsor class: OTHER
First posted: 2016-04-14
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this prospective randomized and double blind controlled study is to evaluate the efficacy and safety of Sulodexide (25 mg) in the treatment of chronic idiopathic subjective tinnitus.

Detailed description: Patients with chronic idiopathic subjective tinnitus, since at least 1 year, re recruited from our Ear, Nose and Throat (ENT) clinic. After verification of inclusion and exclusion criteria, patients consenting to enter the study are assigned randomly to one of the following groups: 1- Sulodexide 25 mg for 40 days 2- Placebo for 40 days. Clinical evaluation of the patient is performed; tinnitus is assessed according to Tinnitus Handicap Inventory score, Mini Tinnitus Questionnaire score. Adverse effects are also noted. Patients are followed at 40 days post-treatment and outcome measures are assessed.

Eligibility criteria: Inclusion Criteria:

* Tinnitus for minimum of 1 year
* Absence of psychiatric or neurological diseases
* Absence of any disease that explains tinnitus
* Noise-induced hearing loss
* Cochlear and retro-cochlear damage

Exclusion Criteria:

* Conductive hearing loss
* Mixed hearing loss
* Meniere's disease
* Systemic vascular disease
* Diabetic disease
* Vestibular schwannoma
* Cerebello-pontine angle tumors
* Pulsatile tinnitus
* Pregnancy

Primary outcomes:
measure: Tinnitus Handicap Inventory (THI)
timeFrame: At day 0 and at 40 days
Secondary outcomes:
measure: Mini Tinnitus Questionnaire (Mini-TQ)
timeFrame: At day 0 and at 40 days
measure: Adverse effects
timeFrame: Up to 40 days
Other outcomes:
Locations:
city: Beirut
country: Lebanon
facility: St Jospeh University
Study officials:
affiliation: Faculty of Medicine - St Joseph University
name: Elias Eter, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00837070: Percutaneous Rupture of Zygapophyseal Joint Cysts
Official title: Percutaneous Rupture of Zygapophyseal Joint Cysts
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Zygapophyseal Synovial Joint Cyst
Keywords: Zygapophyseal
joint
cyst
Fluoroscopy
guided
percutaneous
Lumbar
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2009-02-05
Enrollment: 26
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Lumbar zygapophyseal joint cysts can cause lower extremity radiculopathy. These cysts can be cured by a minimally invasive technique: percutaneous cyst distention and rupture

Detailed description: Lumbar zygapophyseal joint cysts can cause lower extremity radiculopathy. These cysts can be cured by a minimally invasive technique: percutaneous cyst distention and rupture.

30 patient with lower extremity radiculopathy caused by lumbar zygapophyseal joint cysts will be included in the study.

Eligibility criteria: Inclusion Criteria:

* Patients with lumbar zygapophyseal joint cyst and compression of a spinal nerve root with lower extremity radiculopathy proven by MRI.

Exclusion Criteria:

* Infection, uncontrollable bleeding disorder

Primary outcomes:
measure: VAS(Visual analogue scale)for extremity pain
timeFrame: 1-3 and 12 months after intervention
Secondary outcomes:
measure: Roland-Morris disability index
timeFrame: 1-3 and 12 months after intervention
measure: Reduction of cyst size based om T2 MRI
timeFrame: 3 and 12 months after intervention
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Departement of Neuroradiology Oslo university hospital avd Ullevaal
Study officials:
affiliation: Oslo University Hospital
name: Øivind Gjertsen, Md, Msc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00356070: Treatment of Prisoners With Attention Deficit Hyperactive Disorder in Trondheim Prison
Official title: Treatment of Prisoners With Attention Deficit Hyperactive Disorder in Trondheim Prison
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Attention Deficit Hyperactivity Disorder
Keywords: Attention Deficit Hyperactivity Disorder, treatment,
Strattera,
rehabilitation
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
First posted: 2006-07-25
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The treatment of ADHD in jail will help the prisoners in their rehabilitation process

Detailed description: Prisoners with ADHD will be offered treatment with Stratera, and we wanted to study their use of the prisons rehabilitation offers as school, programs and work training before and after treatment with Stratera.

Eligibility criteria: Inclusion Criteria:

All prisoners that fullfill the diagnostic criterias for ADHD -

Exclusion Criteria:

All other prisoners -

Primary outcomes:
measure: The symptoms of Attention Deficit Hyperactive Disorders and the prisoners use of the prisons rehabilitation services before and after treatment will be measured
Secondary outcomes:
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: St. Olavs Hospital. Departement for forensic psyciatry, Brøset.
Study officials:
affiliation: St. Olavs Hospital, Departement of forensic psychiatry, Brøset
name: Roger Almvik, md phd
role: PRINCIPAL_INVESTIGATOR
References: